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Background: Patients with early stage melanoma have high survival rates but require long-term follow-up to detect
recurrences and/or new primary tumours. Shared care between melanoma specialists and general practitioners is an
increasingly important approach to meeting the needs of a growing population of melanoma survivors.
Methods: In-depth qualitative study based on semi-structured interviews with 16 clinicians (surgical oncologists,
dermatologists and melanoma unit GPs) who conduct post-treatment follow-up at two of Australia’s largest
specialist referral melanoma treatment and diagnosis units. Interviews were recorded, transcribed and analysed to
identify approaches to shared care in follow-up, variations in practice, and explanations of these.
Results: Melanoma unit clinicians utilised shared care in the follow-up of patients with early stage melanoma.
Schedules were determined by patients’ clinical risk profiles. Final arrangements for delivery of those schedules (by
whom and where) were influenced by additional psychosocial, professional and organizational considerations. Four
models of shared care were described: (a) surgical oncologist alternating with dermatologist (in-house or local to
patient); (b) melanoma unit dermatologist and other local doctor (e.g. family physician); (c) surgical oncologist and
local doctor; or (d) melanoma physician and local doctor.
Conclusions: These models of shared care offer alternative solutions to managing the requirements for long-term
follow-up of a growing number of patients with stage I/II melanoma, and warrant further comparative evaluation of
outcomes in clinical trials, with detailed cost/benefit analyses.
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Post-treatment follow-up is an important component of
cancer care [1]. In many countries there is growing de-
mand for oncology services and physician assistants and
nurse practitioners have evolved in response to this de-
mand [2-4]. There is also growing awareness of the im-
portant role of general practitioners, both in cancer
management and in post-treatment follow-up [5-7]. A* Correspondence: lucie.rychetnik@sydney.edu.au
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reproduction in any medium, provided the ornumber of ‘shared care’ approaches have been described,
including patients alternating follow-up visits between
the oncologist and their local GP [8-10], or attending
‘specialist’ or ‘shared care’ GPs [11-13].
Melanoma is a growing burden worldwide and the
fourth most common cancer in Australia [14-16].
Patients with AJCC stage I/II melanoma have high sur-
vival rates [17], but require long-term follow-up to de-
tect recurrences and/or new primary tumours [18,19].
Melanoma patients also experience significant anxiety
related to their disease [20]. Routine follow-up can pro-
vide reassurance but attending for follow-up can itself
be a source of anxiety, and a burden in terms of time,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Specialty and gender of study participants
Clinician characteristics (Total n= 16)
Specialty Surgical Oncology 7
Dermatology 5
Primary Care, with focus on melanoma follow-up 4
Gender Male 12
Female 4
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oma specialists and local doctors is one solution to
meeting the care needs of a growing population of mel-
anoma survivors [22]. Some GPs may feel hesitant due
to concerns about skills and capacity [23,24], but trials
of GP-led care have been well received by GPs and
patients in the UK [13,23,25-27]. In Australia, oncology
specialists working in the field of breast cancer have also
reported high levels of willingness to share care with
other health professionals, but only 15% of their patients
attended GPs for post-treatment follow-up [28]. The
proportion of melanoma follow-up conducted as shared
care is currently unknown. And while GP and patient
experiences of shared care in melanoma follow-up have
been described [26,27], no studies have examined shared
care from the perspective of melanoma clinicians.
The purpose of this study was to examine specialist
melanoma clinicians’ perspectives on the provision of
post-treatment follow-up for patients with early stage
melanoma in order to understand and inform future re-
search on optimal models of care. In this paper we de-
scribe approaches to shared care in the follow-up of
patients with AJCC stage I/II melanoma among melan-
oma specialists (surgical oncologists, dermatologists)
and melanoma unit GPs (i.e. GPs based in a specialist
melanoma unit and trained in melanoma follow-up); and
outline four models of shared care as practiced in two of
Australia’s largest tertiary referral melanoma diagnostic
and treatment units. Melanoma specialists views on the
overall functions of follow-up and follow-up intervals
have been reported separately [29].
Methods
This qualitative study was conducted in collaboration
with two melanoma units in NSW, Australia. Melanoma
Institute Australia (MIA) is one of the largest melanoma
treatment units in the world and hosts the clinics of sur-
gical oncologists and dermatologists, as well as melan-
oma unit GPs who conduct follow-up in some of its
surgeons’ practices. The Sydney Melanoma Diagnostic
Centre (SMDC) provides dermatology services and long-
term monitoring of patients at high risk of primary mel-
anoma, including those with previously treated disease.
All clinicians at these units involved in post-treatment
follow-up of patients with stage I/II melanoma were
invited to participate in an in-depth, semi-structured
interview about the nature and provision of follow-up
care. All those invited (n=17) consented but one inter-
view did not eventuate due to difficulties in finding a
suitable time and 16 interviews were completed. The
specialty and gender of participants are reported in
Table 1. The study was approved by the Sydney South
West Area Health Service Ethics Review Committee
(Protocol No X09-0364).The interviews were conducted by three researchers
(LR, RM or KM) and based on an interview schedule
(Appendix 1). This schedule was developed following a
systematic review of the literature [21] and consultations
with melanoma clinicians. The interviews, each lasting
30–60 minutes, were conducted face-to-face (n=12) or
by telephone (n=4) and all were recorded and tran-
scribed. Analysis was conducted as a group process in
which the researchers (LR, RM and KM) read all tran-
scripts and independently prepared analytical notes that
were discussed in regular meetings where the develop-
ment of key categories was revised and refined [30,31].
The practice of shared care in melanoma follow-up was
identified as an important category in the initial stages
of analysis, and the commonalities and variations in
practice, and potential explanations of these, were subse-
quently explored in the data [30,31]. Two participating
clinicians were invited to provide feedback on the valid-
ity of these findings.Results
Shared responsibilities in melanoma follow-up
Long term routine follow-up for stage I/II melanoma
was often conducted as a form of shared care in which
patients alternated between different clinicians at the
melanoma units and/or their local / referring GP or skin
cancer clinic.a The melanoma unit clinicians noted a
paucity of evidence on best practice in melanoma fol-
low-up, and therefore follow-up schedules were primar-
ily based on each patient’s expected risk of recurrence
and of developing a new primary tumour, as well as on
clinical guidelines [18]. A patient’s need for reassurance
or further education to reinforce skin self-examination
or sun-protective behaviours also influenced the recom-
mended frequency of visits - especially in the first two
years.
There was variation in whether, and for how long, sur-
gical oncologists participated in long-term follow-up of
patients with stage I/II melanoma; and for those who
did, whether they themselves regularly conducted full
body skin examinations as part of follow-up visits. Some
surgical oncologists routinely referred patients with early
stage melanoma to other clinicians for long-term follow-
up e.g. to dermatologists at the melanoma unit (or if
Table 2 Factors considered in melanoma follow-up that determined the use of shared care-a summary of melanoma
clinicians’ perspective
‘CONTINUING CARE’ factors Variables ‘COMMUNITY REFERRAL’ factors
Inclined melanoma unit clinicians towards specialist or ‘in-
house’ follow-up e.g. by surgeon or melanoma unit
dermatologist or melanoma GP
Inclined melanoma unit clinicians towards enabling follow-up
by community doctors e.g. dermatologist, local GP or skin
cancer clinic
▪ Higher risk of recurrence or new primary disease (prior
melanoma, tumor thickness, ulceration, mitotic rate, family
history, skin type, number of moles etc)
Clinical ▪ Lower risk of recurrence or new primary disease
▪ Indications for extended post-surgical monitoring e.g. pain,
hematomas, lymphodema, affected functioning




▪ Proximity and travel to unit pose significant burdens; potential
barrier for patient attending scheduled visits (live far away, have
poor mobility etc)▪ Patient allegiance to specialist with preference for attending
with them personally ▪ Patient prefers follow-up with own family physician or local
referring doctor, or happy to participate in shared care
▪ Patient very anxious; requires high emotional support and
reassurance
▪ Patient organizes and coordinates follow-up with preferred
providers and follow-up consistent with recommended
schedule
▪ Patient uncomfortable with referral to local doctor for
follow-up ▪ Patient knowledgeable, confident and conscientious in
conducting skin self-examination▪ Patient lackadaisical about skin surveillance and needs
ongoing education and reinforcement of self examination
▪ Patient lives close by or is able and willing to travel to unit for
appointments
▪ Emphasis on specialisation in follow-up; ie specialist training




▪ Professionally comfortable with sharing follow-up with non-
specialist clinicians; especially when preferred by patient and/or
addresses other psychosocial needs
▪ Sense of overall responsibility for ones patients; professional
obligation to provide ongoing care or oversee quality of skin
surveillance provided by others
▪ Sense of obligation to expand capacity of one’s practice to
accommodate new melanoma patients
▪ Value of health system efficiency and maximizing benefits for
greatest number of patients i.e. focusing specialist care for those
at greatest need / highest risk
▪ Value of knowing patient well and patient-doctor rapport to
facilitate education, early diagnosis and treatment ie doctor is
familiar with patients’ skin, character, lifestyle, preferences; and
patient comfortable to ask questions or return if worried
▪ Value of efficient care for individual patients i.e. reducing
burdens of travel and cost of follow-up relative to clinical
returns for those with lowest risk of disease▪ Clinical interest in observing surgical and clinical outcomes
over the long-term; being able to personally monitor
developments
▪ Enjoyment of psychosocial aspects of follow-up ie regular
contact with ‘well’ patients
▪ Professional courtesy and goodwill towards referring doctor;
inclined to offer continued contribution to follow-up even if
specialist in-put not clinically necessary




▪ Local doctor perceived to be knowledgeable, skilled and
competent in providing melanoma follow-up 1
▪ Local doctor’s skills and interest in follow-up unknown;
specialist feels need to supervise follow-up more closely
▪ Local doctor known to melanoma unit; eg has other
successful shared care arrangements with specialist clinicians
▪ Patient has no or poor relationship with local doctors ▪ Local doctor known to be interested and motivated to
conduct melanoma follow-up
▪ Specialist or patient perceive local doctor not to have the
knowledge, skills, capacity or interest to conduct melanoma
follow-up
▪ Patient has established good and trusting relationship with
local doctor
▪ Value of research roles and responsibilities of specialist unit;




▪ Limited capacity of specialist melanoma unit clinicians
(surgical oncologists in particular) to provide long-term routine
skin surveillance for patients at low risk of recurrence or new
disease
▪ Institutional benefits of constituency and support-base for a
specialist unit from maintaining ongoing relationships with
current and past patients
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or other referring doctor. Other surgical oncologists re-
ferred to one of several melanoma unit GPs, who are co-
located in the melanoma unit facilities and to whom the
surgical oncologists provide specialist support.
Surgical oncologists who preferred to retain greater,
ongoing personal involvement in patients’ follow-up usu-
ally opted for shared care in the form of alternating vis-
its with either a melanoma unit dermatologist or the
patient’s local doctor. Although surgical oncologists pre-
ferred to focus on the wound site and detecting recur-
rences, they also described conducting full-body skin
examinations if their patient had not received a compre-
hensive skin check elsewhere. Finally, surgical oncolo-
gists also described determining their own continued
involvement in follow-up by a weighing patient’s clinical
risks against logistic considerations. Thus they per-
formed skin checks for patients who lived in remote
country towns without access to a skin specialist, or
organized follow-up with a local doctor for those with
limited capacity for travel. The latter option was espe-
cially valued if the local doctor already had a good rela-
tionship with the melanoma unit and/or the patient and
expressed interest in contributing to their follow-up.
The melanoma unit GPs and dermatologists identified
long-term routine skin surveillance of patients with stage
I/II melanoma as their primary responsibility, however
they often also shared follow-up with other community-
based doctors and two main approaches to shared care
were identified. Some considered shared care as a way of
providing for the psychosocial needs of anxious patients
i.e. providing additional follow-up and reassurance for
those who wanted more regular skin checks than was
indicated by their risk profile. But others were more
comfortable to alternate the clinically recommended
schedule of skin checks with the patients’ local doctor.
This partly depended on feedback from patients i.e. by
instructing patients on what to look for, melanoma clini-
cians felt able to trust the capacity of many of their
patients to make an assessment of skin examinations
received elsewhere.
To conclude, recommended schedules for the follow-
up of individual patients were primarily determined by
their risk profile, but final arrangements for the delivery
of those schedules (i.e. by whom and where) were influ-
enced by many other considerations. Table 2 provides a
summary of the multiple and competing variables that
were reported by melanoma clinicians to influence the
practice of shared care. The factors listed under ‘Con-
tinuing Care’ inclined melanoma specialists to either
conduct follow-up themselves or refer to ‘in-house’ mel-
anoma unit GPs. ‘Community Referral’ factors inclined
melanoma unit clinicians to refer patients to attend
follow-up with their local or referring doctor. Inweighing factors in these two categories, the melanoma
unit clinicians determined whether follow-up was best
shared ‘in-house’ or with other clinicians – or indeed if
and when patients were referred for sole follow-up with
their local doctor.
The important variables that impact on shared care
are further sub-divided as follows: patient clinical and
psychosocial variables; melanoma clinician variables;
community doctor variables; and organizational (melan-
oma unit) variables. For example, patient characteristics
included: patients’ overall risk of recurrence and new
primary disease, patient preferences for follow-up, their
level of anxiety and need for information and reassur-
ance, and overall confidence in the alternative follow-up
options. The melanoma clinician variables included dif-
ferent perspectives regarding their own and other clini-
cians’ roles and responsibilities in long-term melanoma
follow-up. Community doctor variables related to the
availability and reliability (sometimes based on feedback
from patients) of the follow-up by the patient’s local or
referring doctor. Finally, organizational factors were also
identified by clinicians as important considerations in
follow-up, including the finite capacity of a specialist
melanoma unit to cope with ever-increasing numbers of
patients requiring follow-up, and its additional functions
in melanoma research (including accurate database
maintenance).
Four models of shared care
The four main models of shared care for early stage mel-
anoma, as reported by the melanoma unit clinicians in
this study, are summarized in Figure 1. These models
were established through formal doctor-to-doctor refer-
ral or arranged by patients themselves. It is important to
note that while the models reflect the most commonly
discussed shared care arrangements, they do not reflect
all possible variations of practice, and are not mutually
exclusive. For example, shared care arrangements would
sometimes change due to a patient’s altered clinical or
social circumstances, or over time as the risk of recur-
rence decreased.
Model (a) comprised alternating visits with the surgi-
cal oncologist and a dermatologist, who was either based
at the melanoma unit or local to the patient. This model
of shared care could continue for different lengths of
time (e.g. between 2 to 5 years post-treatment) after
which on-going skin surveillance would be fully trans-
ferred to the dermatologist. Alternatively, model (b)
comprised early handover by the surgical oncologists
(e.g. after 1 or 2 visits) for ongoing post-treatment fol-
low-up with a dermatologist. The dermatologist may
then subsequently also share follow-up care with the
patient’s own GP or skin cancer clinic who had originally
referred the patient.
(a)  Surgical oncologist and dermatologist
Alternating visits with surgical oncologist and dermatologist (at melanoma unit or local to patient), with shared arrangement 
ongoing for variable duration (e.g. 2-5 years).
(b) Dermatologist and local GP
Dermatologist (at melanoma unit or local to patient) conducts ongoing follow-up; they may also share care with the patient’s
local / referring doctor (e.g. GP or skin cancer clinic). 
(c) Surgical oncologist and local GP
Alternating visits with surgical oncologist and patient’s local / referring doctor (e.g. GP or skin cancer clinic), with variable 
duration of shared arrangements (from a few years to lifelong).
(d) Melanoma unit GP and local GP
Surgical oncologist referral to ‘in-house’ melanoma unit GP for ongoing follow-up; the latter may then also share care with 
patients local / referring doctor (e.g. family GP or skin cancer clinic)
Figure 1 Four described models of shared care.
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oncologist and the patient’s own local GP or skin cancer
clinic. The duration of the shared care arrangements
represented in model (c) was highly variable; some surgi-
cal oncologists reported alternating follow-up with thelocal doctor for a few years only post-treatment, but
others described long-term or ongoing involvement in
follow-up (e.g. for 10 or 15 years post-diagnosis), espe-
cially for those patients who specifically requested that
they continue to see them.
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surgeon (e.g. after 1 or 2 visits) for ongoing post-
treatment follow-up with one of the melanoma unit
GPs. Sometimes the preferred arrangement was a
slightly longer period of alternating visits between the
two before the melanoma unit GP took over. For many
patients, particularly those for whom travel was a signifi-
cant burden, the melanoma unit GPs then also shared
subsequent follow-up visits with the patient’s local /re-
ferring dermatologist, GP or skin cancer clinic. Model
(d) enabled participating surgical oncologists and melan-
oma unit GPs to accommodate many of the ‘Continued
Care’ factors in Table 2, but within a framework that re-
lied on a less intensive use of specialists.
While model (a) was described as providing the high-
est level of specialist care, it was also recognized as
highly resource intensive. The prolonged involvement of
a surgical oncologist was also perceived by some melan-
oma unit clinicians as more than absolutely required for
the majority of patients with stage I/II melanoma. As
outlined in models (a) and (c), however, some surgical
oncologists had ongoing involvement in follow-up, de-
scribing their sense of duty to continue to see patients
they had treated if that was what those patients particu-
larly requested. Shared care with local doctors relied on
less intensive use of melanoma units, and for those liv-
ing further away also reduced financial and travel
burdens.
Model (d) required the least involvement of surgical
oncology and dermatology specialists. Yet views on this
arrangement varied, and a few specialists expressed un-
certainty about the appropriateness of routine skin sur-
veillance in a specialist tertiary referral unit being
undertaken by the melanoma unit GPs, rather than only
by surgical oncologists or dermatologists. Alternatively,
those supporting model (d) said that because patients
were being seen by GPs with an expressed interest and
in-house training in melanoma follow-up, and with
ready access to support from specialist colleagues, it pro-
vided better quality assurance for long term monitoring
than referrals elsewhere. Model (d) was also recognized
to provide accurate information for the unit’s database
of patient records, which supports longitudinal melan-
oma research.
Discussion
Australia has one of the highest rates of cutaneous mel-
anoma in the world, with a growing population of
patients requiring long-term post-treatment follow-up
[14,18,32]. The majority of melanoma specialists are
based in metropolitan areas and there is increasing de-
mand for their services. This qualitative study offers
valuable insights into the practice of shared care by mel-
anoma unit clinicians, which is an important aspect ofthe provision of post-treatment follow-up for a growing
population of melanoma survivors. As described in the
study, melanoma specialists valued shared care in the
follow-up of patients with stage I/II melanoma to ac-
commodate the needs of their patients, and to manage
the finite capacity of specialised units to provide routine
skin surveillance. Patients’ clinical risk factors influenced
follow-up options, as well as psychosocial and logistic
considerations, such as patients’ anxiety or the distance
between home and the melanoma unit and the patients’
capacity to travel. We describe the nature and range of
factors that may be considered and weighed by melan-
oma specialists in their practice of shared care, and
present four models of shared care from two of Austra-
lia’s largest melanoma units. It should be acknowledged
however, that the perspectives reported in this study
may differ from those clinicians who provide post-
treatment melanoma follow-up in other settings, such as
dermatologists not affiliated with melanoma units, GPs
based in skin cancer clinics, or other GPs. Other melan-
oma units may also adopt alternative or additional mod-
els of shared care.
Many patients with AJCC stage I/II melanoma have a
greater risk of developing a new primary melanoma than
a recurrence [33]. In Australia the 10 year risk of mortal-
ity for melanomas with a Breslow thickness ≤1 mm is
less than half the 10 year risk of developing a second pri-
mary melanoma, but for tumours with a Breslow thick-
ness >1 mm the 10 year risk of mortality is substantially
greater [34,35]. Although responsibility for detecting re-
currence is not restricted to melanoma unit clinicians,
improved treatment options may incline melanoma units
more towards identifying options to provide continued
‘in-house’ follow-up for patients with thicker tumours.
The described model (d) of specialists referring follow-
up to melanoma unit GPs is a relatively new approach,
which expands the capacity of a melanoma unit to pro-
vide follow-up by GPs who have greater access to spe-
cialist support than is available to most community GPs.
Although this model does not overcome the burdens of
time and travel that are reported by some patients as
barriers to adherence with schedules [21], this was partly
addressed by the melanoma unit GPs also sharing
follow-up with other community-based doctors.
Patients also value GP participation in cancer fol-
low-up, particularly for navigating the health system
and providing information and psychosocial support
[27,36,37]. Other models of shared care reported else-
where have included community-based ‘shared care’
GPs who conduct follow-up for all cancers, including
melanoma [13], and local GP-led melanoma follow-up
supported by additional training and improved sys-
tems of referral to melanoma specialists when suspi-
cious lesions are found [25]. All forms of shared care
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clinicians, and these must also be understood by
patients themselves [38]. Australian patient perspec-
tives on the benefits and challenges of long term
follow-up of stage I/II melanoma have also been
reported [39]. Melanoma follow-up requires long-term
commitment to regular skin surveillance and many
patients may benefit from increased opportunities to
plan in advance how this can be achieved. Explicit
discussion of alternative options for post-treatment
follow-up could become a formal part of patients’
considerations of treatment referral options. Printed
patient information describing all available models for
their follow-up, including who would conduct each
aspect, qualifications and training of the practitioners,
and any associated costs, could greatly assist this
process.
Conclusion
Melanoma clinicians consider many competing factors
when they determine an appropriate model of follow-
up care for their patients. A number of alternative
models of shared care have been described, which rely
on different levels of contribution from surgical
oncologists, dermatologists and general practitioners.
These models of shared care offer solutions to man-
aging the requirements for long-term follow-up of a
growing number of patients with AJCC stage I/II mel-
anoma, and warrant further comparative evaluation of
outcomes in clinical trials, with detailed cost/benefit
analyses.
Endnote
aAustralia has a growing number of skin cancer clinics
which are mostly staffed by general practitioners. They
offer skin examinations and skin cancer diagnostic and
treatment services, as well as referrals to specialists and
specialist melanoma units
Appendix A. Clinician interview schedule
A.1. Overall objectives of follow-up and clinician
perspectives of patient needs
1. If we could start quite broadly, what would you say
are your main aims in undertaking regular follow-up
and monitoring for patients who have had a stage 1
or 2 primary melanoma?
2. What do you see as your main responsibility in
relation to follow-up and monitoring for your
melanoma patients?
3. What would you consider to be more within the
scope / role / responsibility of other clinicians?
4. In terms of follow-up of people with stage 1 or 2
melanoma, what would you say are some of thesimilarities and differences between SMDC and the
MIA?
A.2. Clinicians own needs, experiences and motivations
for follow-up
5. What about yourself – what would you say are some
of the main benefits for you personally as a
practitioner from having the opportunity to regularly
see your follow-up patients?
6. How does it compare to some of the other clinical
work that you do in terms of job satisfaction or
enjoyment?
7. Do you ever worry about missing a melanoma?
8. Do you think there are any medico-legal
implications?
A.3. Patient experiences as perceived by clinicians
9. From your experience, what would you say are the
main things the patients want from coming to see
you for regular follow-up?
10. Do patients ever talk about how they felt before or
after their appointment, how they are feeling while
they are here?
A.4. Factors influencing follow-up intervals and any
implications for change
11. In terms of the time interval between appointments
– how do you determine how often a patient should
attend?
12. If there was good evidence that recurrence-
detection rates and clinical outcomes were not
affected by increasing the time interval between
follow-up appointments (say from 6monthly to
yearly) what other factors would you and your
patients want to consider when reviewing intervals
between appointments?
A.5. Monitoring undertaken by others
13. Are there any aspects of follow-up care that are
currently being done by others at SMDC or in the
future could be done just as well or more efficiently
for your patients?
14. Do you ever refer patients for follow up or skin
checks with a local GP or a dermatologist other
than at SMDC?
15. What are your thoughts on other possible benefits
from following up patients over the long term, such
as research benefits?
16. Do you refer any of your follow-up patients for skin
photography?
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17. Are you involved in follow-up patient education?
What types of patient education do you do?
18. Is there anything else that you would like to see
included in the follow-up or monitoring process?
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